Research programme: P2X7 receptor antagonists - Asahi Kasei Pharma/RaQualia Pharma

Drug Profile

Research programme: P2X7 receptor antagonists - Asahi Kasei Pharma/RaQualia Pharma

Alternative Names: AKP-23494954; RQ-00466479

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asahi Kasei Pharma Corp; RaQualia Pharma
  • Class Analgesics
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 26 Mar 2018 Asahi Kasei Pharma obtains worldwide license for AKP-23494954/RQ-00466479
  • 26 Mar 2018 Preclinical trials in Neuropathic pain in Japan (unspecified route)
  • 19 Nov 2013 Early research in Undefined indication in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top